Process for the enantioselective synthesis of 2(R)-benzylsuccinic acid
monoamide derivatives
    1.
    发明授权
    Process for the enantioselective synthesis of 2(R)-benzylsuccinic acid monoamide derivatives 失效
    2(R) - 苄基琥珀酸单酰胺衍生物的对映选择性合成方法

    公开(公告)号:US5321139A

    公开(公告)日:1994-06-14

    申请号:US22887

    申请日:1993-02-16

    摘要: Two processes are described for the preparation of the optically pure compounds of formula 1: ##STR1## in which R.sup.1 and R.sup.2 are e.g. alkyl, R.sup.3 and R.sup.4 are e.g. hydrogen and R.sup.5 is e.g. hydrogen. Both processes include, as key steps, the enantioselective hydrogenation of a C.dbd.C double bond and the regioselective formation of a dicarboxylic acid monoamide derivative. In one process a phenylitaconic acid derivative is asymmetrically hydrogenated to give an optically active (R)-benzylsuccinic acid which is then converted to a diester, said diester being converted to the monoamide compound of formula 1. In the second process, a phenylitaconic acid derivative is converted to its anhydride, and the anhydride is then converted to a monoamide which is then asymmetrically hydrogenated to give the compound of formula 1.

    摘要翻译: 描述了制备光学纯的式1化合物的两种方法:其中R 1和R 2是例如: 烷基,R 3和R 4是例如。 氢和R 5是例如。 氢。 作为关键步骤,两种方法都包括C = C双键的对映选择性氢化和二羧酸单酰胺衍生物的区域选择性形成。 在一个过程中,苯基衣康酸衍生物被不对称氢化,得到光学活性(R) - 苄基琥珀酸,然后将其转化为二酯,所述二酯转化成式1的单酰胺化合物。在第二种方法中,苯基衣康酸衍生物 转化成其酐,然后将酸酐转化为单酰胺,然后将其不对称氢化,得到式1的化合物。

    Alkoxyphenylindolinone derivatives, medicaments containing them and
their use
    2.
    发明授权
    Alkoxyphenylindolinone derivatives, medicaments containing them and their use 失效
    烷氧基吲哚啉酮衍生物,含有它们的药物及其用途

    公开(公告)号:US4882329A

    公开(公告)日:1989-11-21

    申请号:US303996

    申请日:1989-01-30

    CPC分类号: C07D401/12 C07D209/34

    摘要: Calcium antagonists of the formula ##STR1## with R(1), R(2), R(3) and R(4) being, inter alia, H, alkyl, alkoxy, halogen, in some cases phenyl; m being 1-4; n being 0-3; X being CH.sub.2, O, S, CO, CHOH or CR.sub.2, and R(5) being various groups containing nitrogen atoms, are described.They are obtained by reaction of compounds II which are likewise new and which contain in place of R(5) a leaving group Y (Cl, Br, I) with the appropriate (cyclic) amino compound.Another synthesis comprises reaction of the appropriate indolinone derivative IV which has a non-etherified hydroxyl group with a side chain which contains a terminal leaving group Z (Cl, Br, I) in the presence of a base.Furthermore, indolinone derivatives VI with an ether side chain with a terminal epoxide group can be reacted with (cyclic) amines to give compounds I.

    摘要翻译: 具有R(1),R(2),R(3)和R(4)的式(I)的化合物拮抗剂尤其是H,烷基,烷氧基,卤素,在一些情况下为苯基; m为1-4; n为0-3; X是CH 2,O,S,CO,CHOH或CR 2,R(5)是含有氮原子的各种基团。 它们通过同样新的且含有代替R(5)离去基团Y(Cl,Br,I)的化合物II与适当的(环状)氨基化合物反应而获得。 另一种合成方法包括在碱存在下,具有非醚化羟基的合适的吲哚啉酮衍生物IV与含有末端离去基团Z(Cl,Br,I)的侧链的反应。 此外,具有末端环氧基团的醚侧链的二氢吲哚衍生物VI可以与(环状)胺反应,得到化合物I.

    Benzothiazine derivatives
    3.
    发明授权
    Benzothiazine derivatives 失效
    苯并噻嗪衍生物

    公开(公告)号:US4595685A

    公开(公告)日:1986-06-17

    申请号:US684711

    申请日:1984-12-21

    摘要: Benzothiazine derivatives of the formula I ##STR1## with (R(1), R(1)', R(1)", R(4) and R(4)' equal to hydrogen, alkyl, alkoxy, halogen, nitro, hydroxyl, acetamido or amino; R(2) equal to hydrogen, alkyl, alkenyl, phenyl; R(3) equal to hydrogen, alkyl, alkenyl, phenyl; R(5) equal to hydrogen or (C.sub.1 -C.sub.3)-alkyl; R(6) equal to one of the following groups, ##STR2## with R(7) and R(8) equal to hydrogen, alkyl, cycloalkyl, phenyl; R(9) equal to hydrogen, alkyl, phenyl, pyridyl, pyrimidinyl or benzoyl; R(10) equal to hydrogen, alkyl, phenyl; R(11) equal to hydrogen, hydroxyl, alkoxy or, together with R(12), a bond; and R(12) equal to hydrogen or, together with R(11), a bond; m equal to 1, 2, 3 or 4; n equal to 0 or 1; p equal to 0, 1, 2, 3 or 4, and X equal to oxygen or two hydrogen atoms, and salts of the compounds of the formula I with physiologically tolerated acids and a process for the preparation of compounds I, likewise a method of treatment of disturbances of the calcium balance of a human body are described.

    摘要翻译: 式(I)与(R(1),R(1)',R(1)“,R(4)和R(4)'等于氢,烷基,烷氧基, 卤素,硝基,羟基,乙酰氨基或氨基; R(2)等于氢,烷基,烯基,苯基; R(3)等于氢,烷基,链烯基,苯基; R(5)等于氢或(C1-C3 ) - 烷基; R(6)等于以下基团之一,其中R(7)和R(8)等于氢,烷基,环烷基,苯基; R(9)等于氢, 烷基,苯基,吡啶基,嘧啶基或苯甲酰基; R(10)等于氢,烷基,苯基; R(11)等于氢,羟基,烷氧基或与R(12) 等于氢或与R(11)一起键; m等于1,2,3或4; n等于0或1; p等于0,1,2,3或4,X等于 氧或两个氢原子,以及式I化合物与生理学上可耐受的酸的盐以及制备化合物I的方法,同样是治疗钙粘蛋白紊乱的方法 描述一个人的身体。

    Novel benzothiazinone derivatives, processes for their preparation,
medicaments containing them and their use
    9.
    发明授权
    Novel benzothiazinone derivatives, processes for their preparation, medicaments containing them and their use 失效
    新的苯并噻嗪酮衍生物,其制备方法,含有它们的药物及其用途

    公开(公告)号:US4831028A

    公开(公告)日:1989-05-16

    申请号:US42867

    申请日:1987-04-24

    CPC分类号: C07D279/16

    摘要: Benzothiazinone derivatives I ##STR1## with R.sup.1 and R.sup.4 being H, alkyl, alkoxy, Hal, CF.sub.3, NO.sub.2, OH, acetamido or amino,R.sup.2 being H, (cyclo)alk(en)yl, cycloalkylakyl, phenyl or phenylalkyl,A being (CH.sub.2).sub.m O(CH.sub.2).sub.n, (CH.sub.2).sub.p --CH(OH)--CH.sub.2).sub.q, (CH.sub.2).sub.p --CH(OCH.sub.3)--(CH.sub.2).sub.q, or (CH.sub.2).sub.r OCH.sub.2 --CO-- and (CH.sub.2).sub.s --CO--,R.sup.5 being NR(6)R(7) or certain cyclic amines, show a calcium-antagonistic action.They are obtained, inter alia, from II ##STR2## by reaction with III ##STR3## A and B are same or different and are lower alkylene having 1 to 6 carbon atoms; and n is 3 to 4.

    摘要翻译: 苯并噻嗪酮衍生物I(I)其中R 1和R 4是H,烷基,烷氧基,卤素,CF 3,NO 2,OH,乙酰氨基或氨基,R 2是H,(环)烷(烯)基,环烷基,苯基或苯基 ,(CH2)mO(CH2)n,(CH2)p-CH(OH)-CH2)q,(CH2)p-CH(OCH3) - (CH2)q或(CH2)rOCH2-CO-和 (CH2)s-CO-,R5是NR(6)R(7)或某些环胺,表现出钙拮抗作用。 它们是通过与III'相互作用而获得的,II'与III'相同或不同,并且是低级亚烷基 具有1至6个碳原子; n为3〜4。